Fully-human 유래 및 TCR 항체 플랫폼

단일 클론 항체

단클론 항체(mAbs)는 높은 특이성, 지속적인 효능 및 향상된 안전성을 제공하여, 목표를 정확하게 겨냥하고 탈목표 효과를 최소화할 수 있습니다. 이들은 종양학 및 기타 질병에서 널리 사용되며, 이중특이성 항체 또는 ADC로 공학될 수 있어 정밀 의학의 기초가 됩니다.
  • 1000+
    표적 프로젝트
  • 1M
    완전 인간형
    항체 서열
  • 450+
    항체 자산 파트너십

이 페이지에서

  • Biocytogen의 mAb 플랫폼의 장점
  • Biocytogen의 RenMab 기반 mAbs 플랫폼
  • FAQs

포스터

모두 보기

    Biocytogen의 mAbs 플랫폼의 장점

    • RenMab를 통해 생성된 고친화력 완전 인간 항체는 인간화 과정을 없애고 개발 기간을 단축시킵니다.
    • GPCRs, 이온 채널, 종양 미세 환경 관련 항원과 같은 복잡한 타겟에 대한 항체 개발을 지원하여 광범위한 적용 가능성을 보장합니다.
    • 이 플랫폼은 in vitro 및 in vivo 기능 검증, 효능 테스트 및 모델 평가를 통합하여 후보 분자의 선별 및 최적화를 가속화합니다.
    • 항체 발견에서 전임상 검증에 이르는 엔드 투 엔드 서비스를 제공하여 공동 개발, 라이선스 및 전략적 파트너십을 지원합니다.

    Biocytogen의 RenMab 기반 mAbs 플랫폼

    RenLite 마우스에서 개발된 BsADC

    MAbs developed from RenMab mice img

    Frequently Asked Questions (FAQs) About Monoclonal Antibody Platform

    1. What are monoclonal antibodies, and how can they support drug development?

    Monoclonal antibodies (mAbs) are antibodies derived from a single clone that recognize a specific epitope on a target antigen. As therapeutics, they can block signaling, neutralize disease-related molecules, or recruit immune responses. Beyond conventional applications, they can also serve as building blocks for antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), antibody-peptide conjugates (APCs) and bispecific antibodies. Their variable regions can be engineered into single-chain variable fragments (scFvs) that serve as antigen-recognition domains in CAR-T therapies.

    2. What types of targets can Biocytogen’s monoclonal antibody platform support?

    Biocytogen’s RenMab® platform generates fully human antibodies against a broad range of therapeutic targets, including GPCRs, ion channels, and tumor microenvironment-associated antigens. For highly conserved targets, RenMab® target gene knockout mice (RenMab® KO) can overcome immune tolerance and broaden epitope coverage.

    3. What factors should guide therapeutic monoclonal antibody candidate selection?

    Selecting therapeutic mAb candidates requires evaluating target relevance, binding affinity and specificity, functional activity, preclinical efficacy, pharmacokinetics, safety, and immunogenicity risk. Developability, including stability, solubility, aggregation propensity, and manufacturability, is also essential.
    Partners can request asset-specific data packages from Biocytogen to assess available evidence and select candidates aligned with their therapeutic goals and development requirements.

    4. Can monoclonal antibodies be developed into other therapeutic formats?

    Yes. RenMab®-derived monoclonal antibody binders can serve as building blocks for other therapeutic formats, including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), antibody-peptide conjugates (APCs), bispecific antibodies and scFv, the key recognition elements of CAR-T. Biocytogen also provides off-the-shelf antibody binders and other discovery platforms to support different molecular design: RenLite® generates fully human common light chain antibodies for bispecific antibodies and BsADCs, while RenNano® generates fully human HCAbs and VHHs.

    5. What collaboration options does Biocytogen offer for monoclonal antibody development?

    Biocytogen supports flexible collaboration opportunities for monoclonal antibody assets from early evaluation to clinical development. Partners can review available assets and evaluate selected candidates through material transfer agreements (MTAs). Following successful evaluation, assets can be licensed through collaboration agreements with upfront and milestone payments to advance selected assets.